Scholarlink

<p>Radiotherapy-induced skin fibrosis is a chronic progressive complication of radiotherapy that impairs function, aesthetics, and quality of life yet remains under-recognized and undertreated. While acute cutaneous toxicities are typically transient, chronic sequelae such as fibrosis, lymphedema, atrophy, telangiectasia, and dyspigmentation reflect uncontrolled tissue remodeling driven by sustained inflammation and fibroblast activation. Ionizing radiation generates reactive oxygen species that initiate vascular and epithelial injury, trigger immune infiltration, and perpetuate a cycle of transforming growth factor-β-driven myofibroblast differentiation, epithelial-to-mesenchymal transition, extracellular matrix deposition, and epigenetic reprogramming. Predicting and grading radiotherapy-induced skin fibrosis remains difficult: physician-reported scales lack sensitivity, and emerging imaging modalities and candidate tissue biomarkers require validation. Therapeutic strategies include pentoxifylline with vitamin E, oral statins, corticosteroids, fractional CO₂ and pulsed dye lasers, autologous fat grafting with adipose-derived stem cells, and manual therapies, each with varying efficacy. Investigational approaches such as deferoxamine, microneedling, and mesenchymal stem cell-based interventions show antifibrotic and regenerative potential, while candidate therapies including topical statins, antioxidants, timolol, tamoxifen, and colchicine remain untested. Despite the rising burden among cancer survivors, many patients do not receive a dermatologic evaluation, and consensus guidelines are limited. Dermatology should lead multi-modal efforts to integrate systemic, topical, and procedural interventions, develop standardized diagnostic frameworks, validate biomarkers, and conduct skin-specific clinical trials. Greater involvement of dermatologists in survivorship care, early referral, and advocacy for policy and funding will be essential to address radiotherapy-induced skin fibrosis and improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiotherapy-Induced Skin Fibrosis: Pathophysiology, Emerging Therapeutics, and the Role of Dermatology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Olivia M. Burke,
  • Sophie M. Bilik,
  • Caroline Dodson,
  • Jordan Johnson,
  • Lina Ferrari,
  • Karina Imisheva,
  • Hannah Pachalis,
  • Victoria Rose Frerichs,
  • Angela Jeffrey,
  • Andrew P. Sawaya,
  • Stuart E. Samuels,
  • Rivka C. Stone

摘要

Radiotherapy-induced skin fibrosis is a chronic progressive complication of radiotherapy that impairs function, aesthetics, and quality of life yet remains under-recognized and undertreated. While acute cutaneous toxicities are typically transient, chronic sequelae such as fibrosis, lymphedema, atrophy, telangiectasia, and dyspigmentation reflect uncontrolled tissue remodeling driven by sustained inflammation and fibroblast activation. Ionizing radiation generates reactive oxygen species that initiate vascular and epithelial injury, trigger immune infiltration, and perpetuate a cycle of transforming growth factor-β-driven myofibroblast differentiation, epithelial-to-mesenchymal transition, extracellular matrix deposition, and epigenetic reprogramming. Predicting and grading radiotherapy-induced skin fibrosis remains difficult: physician-reported scales lack sensitivity, and emerging imaging modalities and candidate tissue biomarkers require validation. Therapeutic strategies include pentoxifylline with vitamin E, oral statins, corticosteroids, fractional CO₂ and pulsed dye lasers, autologous fat grafting with adipose-derived stem cells, and manual therapies, each with varying efficacy. Investigational approaches such as deferoxamine, microneedling, and mesenchymal stem cell-based interventions show antifibrotic and regenerative potential, while candidate therapies including topical statins, antioxidants, timolol, tamoxifen, and colchicine remain untested. Despite the rising burden among cancer survivors, many patients do not receive a dermatologic evaluation, and consensus guidelines are limited. Dermatology should lead multi-modal efforts to integrate systemic, topical, and procedural interventions, develop standardized diagnostic frameworks, validate biomarkers, and conduct skin-specific clinical trials. Greater involvement of dermatologists in survivorship care, early referral, and advocacy for policy and funding will be essential to address radiotherapy-induced skin fibrosis and improve patient outcomes.